Eye Allergy Treatment Market Trends, Key Country Analysis and Forecast to 2027

 Eye Allergy Treatment Market Application And Share Analysis By Type (Vernal Keratoconjunctivitis, Atopic Keratoconjunctivitis, & Contact Allergic Conjunctivitis), Treatment (Medications & Allergy Shots), And End User (Hospitals & Clinics)-Forecast Till 2027

                                          

The Eye Allergy Treatment Market is expected to register CAGR of 5.30% till 2023. Some of the protuberant drivers supporting the growth of global eye allergy treatment market are identified as, increasing prevalence of ophthalmological disorders as rising aging population and changing lifestyle are promoting the rising prevalence of ophthalmological disorders. Favorable government funding by in developed and few developing countries in various government and private organizations are contributing to research and prevention programs for ophthalmic disorders.

Get Sample Report @ https://www.marketresearchfuture.com/sample_request/3811

Eye Allergy Treatment Market - Segmentation

Global Eye Allergy Treatment market has been segmented on the basis of type which comprises of seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, giant papillary conjunctivitis, and others. Vernal keratoconjunctivitis includes palpebral, limbal, corneal, and others.

On the basis of treatment, the market has been segmented into medication, allergy shots (immunotherapy), and others. Medication includes artificial tears, decongestants, oral antihistamines, antihistamine/mast-cell stabilizers, corticosteroids. Decongestants are further sub-segmented into with or without antihistamines. Allergy shots (immunotherapy) is sub-segmented into Subcutaneous Immunotherapy Treatment (SCIT) and Sublingual Immunotherapy Treatment (SLIT).

On the basis of end user, it is segmented into eye hospitals & clinics, medical institutes, research centers, and others.

Global Eye Allergy Treatment Market - Competitive Analysis

Characterized by the presence of several well-established and small players, the global market of eye allergy treatment appears to be highly competitive and fragmented. With well-established market in the North America region major companies like Johnson & Johnson Vision Care, Inc., Merck & Co., Inc., Pfizer Inc, Regeneron Pharmaceuticals, Inc, and various others have their home in the region and generate maximum market share. These companies have expanded their operating unit in various other emerging regions as well. Moreover, the other small and medium scale players are generating revenue from local market.

Top pharmaceutical companies are dominating this market due to various factors such as strong global presence, sales and distribution network, investment in R&D, high quality products, and strong brand image.

Major Players

There are plenty of large and small market players which operate in this market: ALLERGAN (Republic of Ireland), Johnson & Johnson Vision Care, Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), Regeneron Pharmaceuticals, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Santen Pharmaceutical Co., Ltd. (Japan), Valeant (Canada) Shire (Republic of Ireland), and others.

Industry News:

In 2016, Irish pharmaceutical giant Shire received U S Food and Drug Administration (FDA) approval for their dry-eye disease drug, this drug is marketed under the brand name Xiidra.

In 2016, Shire an Irish pharmaceutical company received U.S. Food and Drug Administration (FDA) approval for their dry-eye disease drug, this drug is marketed under the brand name Xiidra. It is the company’s first FDA-approved medicine in ophthalmics and this approval makes an important first step in the group’s determination to become a one of the leader in this market. The product is also the first new drug to treat this condition since Allergan’s Restasis gained an approval in 2002 and label description for Shire’s drug compared very favourably with its competitor.

Moreover, Xiidra is also directed for the treatment of both signs and symptoms of dry eye disease, whereas Restasis was approved by the FDA, only on a demonstrated development in objective signs of dry eye. Earlier the drug was rejected by the FDA in October, when the company was asked for further clinical study, but the company was confident enough that it would satisfy the U.S. regulator.

Browse Complete 76 Pages Premium Research Report Enabled with Tables and Figures @ https://www.marketresearchfuture.com/reports/eye-allergy-treatment-market-3811

Eye Allergy Treatment Market - Regional Analysis

Considering the global scenario of the eye allergy treatment market. America is top revenue generator in global market that is mainly due to some factors like new FDA approvals, aggressive strategies by pharmaceutical companies, increasing investment for R&D as well as clinical trials. European market is the second largest market for eye allergy treatment. Increasing prevalence and growing awareness of eye allergies and its treatments are leading the growth of Asia Pacific eye allergy treatment market. Middle East and Africa eye allergy treatment market is expected to have limited growth because of lack of traditional healthcare practices and slow adoption of new products and therapies.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.